When would you consider first line FOLFOXIRI + Bevacizumab for metastatic colon cancer?

The phase III TRIBE study published in 2015 reported first line FOLFOXIRI with bevacizumab treatment had overall survival (OS) benefit compared with FOLFIRI/bevacizumab as first line treatment (29.8 months vs. 25.8 months, HR 0.80, p=0.03) (Cremolini et al., Lancet Oncol 2015). FOLFOXIRI/bevacizumab...

I consider modified-FOLFOXIRI based chemotherapy (with targeted agents) for most patients and use this frequently. Our colon cancer patients are much more robust than pancreatic patients who receive FOLFIRINOX, in general.

I definitely use this for BRAF mutated patients, those with symptoms or exte...

Great question! It's mportant to consider sidedness as well as the decision to not use anti-EGFR antibody. Here is a great review.